Dear Reader,

We are glad to inform you that we could publish research findings about our diagnostic CTR-Test® (Chemotherapy Resistance Test) within two publications this year:

  • The first publication entitled “New in vitro system to predict chemotherapeutic efficacy of drug combinations in fresh tumor samples” was successfully published in the PeerJ journal.(Link: https://peerj.com/articles/3030.pdf)
     
  • The second publication entitled “Prediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-test)“ was published in the Journal of Ovarian Research. (Link: http://rdcu.be/xNyM).

Both publications are described in detail below.

In addition we would like to inform you, that we perform trainings regarding our offered diagnostics. Further information can be found below in our newsletter.
 

Information about the first publication

“New in vitro system to predict chemotherapeutic efficacy of drug combinations in fresh tumor samples”

This is the first publication of this kind, in which a method is described, how the efficacy of chemotherapeutics combinations practically can be determined on living tumor material for an optimal patient care. Combination therapies with two or more chemotherapeutics are becoming increasingly important for the treatment of cancer. To our knowledge there is no further publication about a method for efficacy testing of drug combinations, which is relevant for patient care. Other approaches in the field of drug discovery, which deal with drug combinations, mainly investigate the development of new combinations. Our method could be important in this field as well.

The CTR-Test®  (Chemotherapy-Resistance-Test) of TherapySelect allows to find the best chemotherapy option for individual cancer patients before start of therapy. With our test system it is possible to determine the efficacy of chemotherapeutics combinations via two different ways: either the direct measurement of the combination or the indirect measurement via the single substances. The most important findings of our publication regarding the testing of chemotherapeutics combinations with help of the CTR-Test are listed below:

  1. When patients are to be treated with a chemotherapeutics combination, they have the best chance to benefit from the CTR-Test if the combination is composed of efficient single substances. This is based on the principle that the best drug combination consists of the most efficient single drugs and the worst combination of the least efficient single drugs.
     
  2.  When according to the guideline or due to any other reasons the treatment with specific drug combinations is planned, the combinations should be tested in addition to the single substances where possible. This enables a more precise prediction of efficacy in a particular case.
     
  3. When drugs should be combined without existing experience, the testing of the combination is useful as well. Thereby potential antagonistic effects could be detected in advance and an incorrect application for the patient can be avoided.

For our experiments we mainly used samples from ovarian carcinoma patients, but also samples from other tumor species. Furthermore we applied different chemotherapeutics. Our results are consistent with all previous publications about this topic, and even go beyond. The publication shows for the first time an effective and functional method for combination measurement. We are very much interested in providing this method also for drug development. Thereby clinical studies could be planned and performed more effectively. Furthermore there is already a patent pending for this new in vitro system for combination testing. 

If you want to read the publication you can find it using the following link: https://peerj.com/articles/3030.pdf. The publication is available in English.
 

Information about the second publication

“Prediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-test)“

Within this publication the results of the CTR-Test were retrospectively correlated with the clinical response of individual ovarian cancer patients. The cancer of these patients was treated at the Charité in Berlin. They were treated with single chemotherapeutics or chemotherapeutics combinations according to guidelines. Our data were subsequently compared to already published data about ovarian cancer and other cancer types. This should be used to validate that the CTR-Test is able to predict resistances or sensitivities of tumors from ovarian cancer patients for chemotherapeutics. We could show that the CTR-Test can detect resistances, and for drug combinations also sensitivities, in ovarian cancer patients very precisely. Our data could confirm or even partially exceed already published data. Therefore our study confirms the functionality and the benefit of the CTR-Test for finding an effective chemotherapy for ovarian cancer patients. The CTR-Test is able to predict the clinical response of patients to a treatment with chemotherapeutics.

If you want to read the publication you can find it using the following link: http://rdcu.be/xNyM. The publication is available in English.
 

Trainings

We offer trainings regarding our diagnostics for interested customers. This is intended to discover the diagnostics and their area of application and to obtain detailed information about them, respectively. These trainings can either take place as part of personal visits with a corresponding number of participants or as online meetings with single participants. If interested please contact us at the below-mentioned contact data.
 

For further questions do not hesitate to contact our team.
Tel: +49 (0)6221-8936-152 oder
Email: contact@therapyselect.de

Sincerely,
Your TherapySelect Team 

Posted on Friday, December 8, 2017